Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain.

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate whether patients who benefit from a personalized pharmaceutical plan (PPP) during their hospitalization, allowing them to be informed and sensitized, are treated for a shorter period of time with strong opioids with a reduced risk of dependence compared to a management according to the usual modalities in the rheumatology services concerned.

Official Title
-----------------
Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain. Multicenter, Randomized, Controlled Study

Conditions
-----------------
Acute Pathology of the Locomotor System

Intervention / Treatment
-----------------
* Other: personalized pharmaceutical plan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient hospitalized in the rheumatology department Patient with acute pain in the context of a non-cancerous, non-traumatic, high-energy musculoskeletal pathology Patient for whom a prescription of strong opioid derivatives is initiated in rheumatology or patient for whom a prescription of strong opioid derivatives is maintained in rheumatology if the initial prescription has a maximum duration of 30 consecutive days prior to inclusion Exclusion Criteria: Patient with cancer or fibromyalgia already diagnosed at inclusion Patient with poor French language skills Taking a strong opioid treatment for more than 30 consecutive days prior to inclusion Person judged by the prescriber or pharmacist as not autonomous for the management of strong opioid treatment Patient already included in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: interventional group<br>benefiting from a multi-professional intervention around the strong opioid treatment with the aim of setting up a personalized pharmaceutical plan | Other: personalized pharmaceutical plan<br>* multi-professional intervention around strong opioid treatment with targeted pharmaceutical interview<br>|
| No Intervention: control group<br>routine management, including medication reconciliation at entry and exit and pharmaceutical analysis of prescriptions | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| total duration of treatment in days with strong opioids from day of inclusion |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of patients exceeding the optimal duration of treatment with strong opioids defined by the SFETD learned society (French Society for the Study and Treatment of Pain) (3 months) |  | 3 months | 
| pain assessment (numerical scale) at first patient call after stopping strong opioids |  | 6 months | 
| number of patients exceeding the optimal duration of treatment with strong opioids defined by the CLUD (Pain Control Committee) of Rouen University Hospital (28 days) |  | 28 days |